8-K: NeuroOne Appoints Med-Tech Veteran Jason Mills to Board

NeuroOne Medical Technologies Corporation announced the appointment of seasoned med-tech executive and analyst Jason Mills to its Board of Directors, effective December 18, 2025.

Summary

• NeuroOne Medical Technologies Corporation increased its Board of Directors size to five members.
• Jason R. Mills was appointed as a Class I director, effective December 18, 2025.
• Mr. Mills will serve on the Compensation and Nominating & Corporate Governance Committees, effective January 1, 2025.
• He brings over two decades of experience as a med-tech investment analyst and currently serves as Executive Vice President of Strategy at NYSE-listed Penumbra, Inc.
• NeuroOne also posted an updated corporate presentation to its website on December 22, 2025, which contains forward-looking statements.

Sentiment

Score: 8

Explanation: The appointment of a highly experienced and well-regarded industry veteran to the board, especially one with strong financial and strategic expertise, is a significant positive development for corporate governance and strategic direction. This typically enhances investor confidence.

Positives

• The appointment of Jason R. Mills, a highly experienced med-tech executive and investment analyst, to the Board of Directors.
• Mr. Mills' background includes leadership roles at Penumbra, Inc., a leading thrombectomy company, and over 13 years as head of medical technology equity research at Canaccord Genuity.
• His expertise in long-range planning, FP&A, business development, investor relations, and capital markets is expected to be a critical resource for NeuroOne's clinical and corporate goals.
• His addition is anticipated to expand the company's reach and create additional shareholder value.

Risks

• Forward-looking statements in the corporate presentation are based on current expectations and are not guarantees of future performance.
• Actual events or results may differ materially from those in the forward-looking statements due to various limitations.

Future Outlook

The company's updated corporate presentation contains forward-looking statements regarding future performance, which are based on current expectations but are not guarantees, and actual results may differ materially.

Management Comments

• "We are privileged to welcome Jason to NeuroOne with his strong background in med-tech in both corporate settings and as an industry investment analyst." Dave Rosa, CEO of NeuroOne.
• "Having known Jason since he was at Canaccord, I know he brings unparalleled and invaluable experience and insights in med-tech." Dave Rosa, CEO of NeuroOne.
• "His firsthand knowledge of our industry, combined with his investment and capital markets expertise, will be a critical resource as we progress on our clinical and corporate goals." Dave Rosa, CEO of NeuroOne.
• "In addition to his service on the Compensation and Nominating & Corporate Governance Committees, Jason will help us expand the breadth and depth of our reach as a company transforming the diagnosis and treatment of neurological disorders, positioning us to create additional value for our shareholders." Paul Buckman, Chairman of the Board of Directors.

Industry Context

The appointment of Jason Mills, a veteran in the med-tech investment and corporate strategy sectors, aligns NeuroOne with broader industry trends emphasizing strong strategic leadership and capital markets expertise. His background with Penumbra, a leader in thrombectomy, suggests a focus on innovative medical technologies for challenging neurological conditions, a growing area within the med-tech industry.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The appointment of a highly respected industry veteran with capital markets expertise is likely to be viewed positively, potentially enhancing shareholder value and confidence in strategic direction.
• Management/Employees: The addition of a strategic leader like Mr. Mills could provide valuable guidance and support for the company's clinical and corporate goals.

Next Steps

• Jason R. Mills to commence service on the Compensation and Nominating & Corporate Governance Committees on January 1, 2025.
• NeuroOne will continue to use its updated corporate presentation in communications or conferences.

Key Dates

Recommendation

The appointment of Jason Mills, a highly respected and experienced med-tech investment analyst and executive, to NeuroOne's Board of Directors is a strong positive signal. His deep industry knowledge, strategic planning expertise from Penumbra, and extensive capital markets background from Canaccord Genuity are invaluable assets. This move significantly strengthens the company's corporate governance, strategic capabilities, and investor relations potential, which should enhance investor confidence and potentially drive future growth and shareholder value. This strategic enhancement suggests a positive outlook for the company's trajectory.

Keywords

NeuroOne Medical Technologies, NMTC, Board of Directors, Jason Mills, Med-Tech, Medical Devices, Corporate Governance, Investment Analyst, Penumbra Inc., Thrombectomy, Neurological Disorders, Epilepsy, Parkinson's Disease, Dystonia, Essential Tremors, Chronic Pain